The aztreonam avibactam mechanism of action involves two complementary roles: aztreonam inhibits bacterial cell-wall synthesis, while avibactam inhibits certain beta-lactamase enzymes that could otherwise destroy aztreonam. This combination is particularly relevant to research on antimicrobial resistance caused by metallo-beta-lactamase (MBL)-producing Gram-negative bacteria.
Understanding how these two agents work together helps explain the scientific rationale behind the combination, its potential role against resistant bacteria, and why laboratory susceptibility testing remains important.
What Is Aztreonam–Avibactam?
Aztreonam–avibactam combines a monobactam antibiotic, aztreonam, with a non-beta-lactam beta-lactamase inhibitor, avibactam.
The two components have different functions:
- Aztreonam: Targets bacterial penicillin-binding proteins involved in cell-wall synthesis.
- Avibactam: Inhibits selected beta-lactamase enzymes that can inactivate susceptible beta-lactam antibiotics.
The combination is designed to address a key resistance problem: some bacteria produce multiple beta-lactamases, including enzymes that can destroy aztreonam even though aztreonam is stable against hydrolysis by metallo-beta-lactamases.
The combination’s activity depends on the bacterial species, its resistance mechanisms, and susceptibility to the agents.
Aztreonam Avibactam Mechanism of Action: Step by Step
1. Aztreonam targets bacterial cell-wall synthesis
Aztreonam belongs to the monobactam class of antibiotics. It binds to susceptible penicillin-binding proteins (PBPs), particularly PBP3 in relevant Gram-negative bacteria.
These proteins participate in the final stages of peptidoglycan synthesis and bacterial cell-wall formation.
When aztreonam inhibits the relevant PBPs, normal cell-wall construction is disrupted. In susceptible bacteria, this can lead to impaired cell-wall integrity and bacterial death.
However, the antibiotic must remain active long enough to reach its target. Bacterial resistance enzymes can interfere with this process.
2. Metallo-beta-lactamases create a major resistance challenge
Metallo-beta-lactamases are enzymes produced by certain bacteria that can break down many beta-lactam antibiotics.
Important examples include:
- New Delhi metallo-beta-lactamase (NDM)
- Verona integron-encoded metallo-beta-lactamase (VIM)
- Imipenemase (IMP)
These enzymes are clinically important because they can compromise several commonly used beta-lactam antibiotics, including carbapenems.
Aztreonam is notable because it is stable against hydrolysis by MBLs. However, this property alone does not guarantee activity against an MBL-producing organism.
Such bacteria may simultaneously produce other beta-lactamases, including extended-spectrum beta-lactamases (ESBLs), AmpC enzymes, and certain OXA-type enzymes. These additional enzymes can inactivate aztreonam.
This is where avibactam’s role becomes important.
3. Avibactam inhibits selected beta-lactamases
Avibactam is a non-beta-lactam beta-lactamase inhibitor. It inhibits several clinically important serine beta-lactamases, including many enzymes in classes A and C and certain class D enzymes.
Examples include many ESBLs, AmpC enzymes, and OXA-48-like enzymes.
By inhibiting susceptible enzymes that could otherwise hydrolyse aztreonam, avibactam can protect aztreonam from enzymatic degradation.
Important distinction: Avibactam does not directly inhibit metallo-beta-lactamases such as NDM, VIM, or IMP. The combination’s scientific rationale relies on aztreonam’s stability against MBL hydrolysis and avibactam’s inhibition of relevant co-produced serine beta-lactamases.
4. The combination helps aztreonam reach its target
When relevant co-produced beta-lactamases are inhibited, aztreonam may remain active long enough to reach its bacterial target.
Aztreonam can then bind to susceptible PBPs and interfere with cell-wall synthesis.
This complementary mechanism explains why aztreonam–avibactam has been investigated for infections caused by certain multidrug-resistant Gram-negative bacteria, particularly MBL-producing Enterobacterales.
Nevertheless, the combination is not active against every resistant organism. Other resistance mechanisms can reduce susceptibility.
How Aztreonam and Avibactam Work Together
| Component | Primary role | Scientific significance |
|---|---|---|
| Aztreonam | Inhibits susceptible PBPs involved in cell-wall synthesis | Its stability against MBL hydrolysis is an important property |
| Avibactam | Inhibits selected serine beta-lactamases | Can protect aztreonam from degradation by susceptible co-produced enzymes |
| Combination | Combines antibacterial activity with enzyme inhibition | May retain activity against selected resistant bacteria when the relevant mechanisms are susceptible |
The components perform complementary functions; avibactam is not simply a second antibiotic with the same target as aztreonam.
Why Is the Combination Relevant to NDM-Producing Bacteria?
NDM-producing bacteria can be difficult to treat because NDM enzymes inactivate many beta-lactam antibiotics.
Aztreonam’s stability against MBL hydrolysis provides a potential way to address one part of this resistance mechanism. Avibactam can inhibit certain additional beta-lactamases that might otherwise destroy aztreonam.
The Infectious Diseases Society of America (IDSA) 2026 guidance identifies aztreonam–avibactam and cefiderocol as preferred treatment options for invasive infections caused by NDM-producing Enterobacterales, subject to the clinical context and relevant susceptibility information.
However, the clinical evidence specifically involving MBL-producing infections remains limited in some patient subgroups. Laboratory findings should not automatically be interpreted as proof of clinical success in every infection.
For additional background, read our related article on Aztreonam–Avibactam and NDM, after confirming that this page is live and covers the relevant topic.
What Are the Limitations of This Mechanism?
Understanding the mechanism of action is important, but it does not establish that every isolate will be susceptible.
Resistance may occur through several pathways.
Changes in penicillin-binding proteins
Alterations in PBP3 can reduce aztreonam’s ability to bind to its target. Certain PBP3 insertions have been associated with resistance in NDM-producing Escherichia coli.
Additional beta-lactamase activity
Some beta-lactamase variants can reduce the effectiveness of the combination, particularly when they affect aztreonam degradation or interact with other resistance mechanisms.
Reduced permeability and increased efflux
Changes in bacterial membrane permeability or increased efflux can reduce the amount of active antibiotic reaching its target.
The contribution of these mechanisms varies by organism and isolate. Their presence and clinical significance must be evaluated using appropriate microbiological evidence.
Why Is Antimicrobial Susceptibility Testing Important?
Antimicrobial susceptibility testing (AST) helps determine whether a bacterial isolate is susceptible to a particular antimicrobial agent under established laboratory criteria.
This is important because the presence of an NDM gene or another resistance marker does not, by itself, establish the full susceptibility profile of an isolate.
Interpretation should use a validated method and current, applicable breakpoints where available. Laboratories should follow relevant CLSI or EUCAST guidance, local requirements, and validated testing procedures.
Susceptibility results must be interpreted alongside the infection site, clinical circumstances, and applicable prescribing information.
Read more in our related resource on Aztreonam–Avibactam Susceptibility Testing, provided the page is available and relevant.
Clinical Significance of Aztreonam–Avibactam
The combination has an important scientific rationale for selected resistant Gram-negative bacteria, especially MBL-producing Enterobacterales.
Its clinical role should be assessed using the totality of available evidence, including:
- The organism and resistance mechanism.
- Validated antimicrobial susceptibility results.
- Relevant clinical-trial evidence.
- Current clinical guidelines.
- The approved prescribing information for the specific product available in the relevant jurisdiction.
In-vitro activity and a plausible mechanism do not guarantee clinical efficacy for every patient or infection.
Product-specific indications, dosage, safety information, preparation instructions, and regulatory status must be confirmed using the applicable official product documentation. Information for one brand should not automatically be transferred to another.
Frequently Asked Questions
What is the mechanism of action of aztreonam–avibactam?
Aztreonam inhibits susceptible penicillin-binding proteins involved in bacterial cell-wall synthesis. Avibactam inhibits selected beta-lactamases that could otherwise inactivate aztreonam, allowing the combination to retain activity against certain resistant bacteria.
Does avibactam directly inhibit NDM?
No. Avibactam does not directly inhibit NDM or other metallo-beta-lactamases. The combination’s rationale is based on aztreonam’s stability against MBL hydrolysis and avibactam’s inhibition of certain co-produced serine beta-lactamases.
Why is aztreonam–avibactam studied in antimicrobial resistance?
Some Gram-negative bacteria produce multiple beta-lactamases. The complementary properties of aztreonam and avibactam may help address selected resistance mechanisms, including those encountered in certain MBL-producing Enterobacterales.
Is aztreonam–avibactam effective against every NDM-producing bacterium?
No. Susceptibility can vary between isolates because of additional beta-lactamases, changes in PBPs, permeability alterations, and other resistance mechanisms. Appropriate susceptibility testing and clinical assessment are essential.
Is the mechanism of action the same as the approved indication?
No. A drug’s mechanism explains how it may work biologically. Its approved indication defines the uses authorised by the relevant regulator for a particular product. These are different concepts and should not be treated as interchangeable.
Conclusion
The aztreonam avibactam mechanism of action is based on two complementary functions: aztreonam inhibits susceptible bacterial cell-wall targets, while avibactam protects it against selected beta-lactamases.
This combination provides a scientific approach to addressing certain antimicrobial-resistance mechanisms, including those found in some MBL-producing Enterobacterales. However, susceptibility is not universal, resistance can emerge, and clinical decisions must be guided by appropriate testing, evidence, clinical judgement, and the applicable product information.
For further reading, explore the related resources on Aztreonam–Avibactam Injection and Aztreonam–Avibactam Injection Uses, after verifying that each page is live and appropriate for the link.
Medical disclaimer: This article is intended for educational and scientific information only. It is not a substitute for professional medical advice, prescribing information, or local antimicrobial-treatment guidelines. Product-specific information must be verified against official documentation.
References
- Infectious Diseases Society of America. 2026 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. https://www.idsociety.org/practice-guideline/amr-guidance/
- Stefani S, et al. Aztreonam and avibactam combination therapy for metallo-β-lactamase-producing gram-negative bacteria: A Narrative Review. Clinical Microbiology and Infection. 2025;31(6):971–978. https://pubmed.ncbi.nlm.nih.gov/39528085/
- Bush K. Past, present, and future perspectives on aztreonam and avibactam. Expert Review of Anti-infective Therapy. 2025;23(5):277–290. https://pubmed.ncbi.nlm.nih.gov/40011051/